Seeking Alpha

Seeking Alpha Portfolio App for iPad

774 people get BRLI articles and Market Currents by email alert.

Get email alerts on BRLI »

BRLI

Bio-Reference Laboratories, Inc.

5/19/2013, 11:26 PM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Monday, May 13, 3:56 PM The 25 most heavily shorted stocks (as a percent of float) in the S&P 1500 as of the end of April are up 6.75% in May, trouncing the S&P's 2.33% gain, according to Bespoke - and this doesn't include Tesla, up 57% with 40% of its float shorted, but not a S&P 1500 member. The top 5 heavily shorted: BTH, QCOR, CSTR, BRLI, SPPI. The rest in another post. 4 Comments
Thursday, February 28, 12:33 PM Bio-Reference Laboratories (BRLI +5.8%) shrugs off a negative article in The Street Sweeper yesterday to trade higher in spite posting a mixed FQ1 earnings report. The company beat on a per share basis but missed on its top line consensus as revenue was impacted from hurrican Sandy. Going forward the company reaffirms its guidance for FY13, still expecting net revenues to increase more than 15% and net income to increase by approximately 20%. Comment! [Healthcare, Earnings, On the Move]
Thursday, February 28, 12:05 AM Notable earnings before Thursday’s open: AIXG, AWR, BDBD, BKS, BRLI, BRY, CHS, CTRX, CVC, DANG, DPZ, GMXR, GTLS, HK, IRDM, IRM, ISIS, KSS, LKQ, MCGC, MTG, NIHD, OCN, PKT, RDC, RNO, SDRL, SHLD, TD, TTI, VRX, WNR, WPX, WWE Comment! [Earnings]
Wednesday, February 27, 5:30 PM Notable earnings before Thursday’s open: AIXG, AWR, BDBD, BKS, BRLI, BRY, CHS, CTRX, CVC, DANG, DPZ, GMXR, GTLS, HK, IRDM, IRM, ISIS, KSS, LKQ, MCGC, MTG, NIHD, OCN, PKT, RDC, RNO, SDRL, SHLD, TD, TTI, VRX, WNR, WPX, WWE Comment! [Earnings]
Wednesday, February 27, 3:24 PM Bio-Reference Labs (BRLI -0.6%) slips on a negative article from short-seller The Street Sweeper. The gist of the article says that the company is likely to be faced with a flood of denials from some of the largest health insurance companies in the country, and that growth projections are overly optimistic. 3 Comments [Healthcare, On the Move]
Thursday, December 6, 2012, 3:35 PM Bio-Reference Laboratories (BRLI +5%) moves up after reporting a largely in-line FQ4, but a 16% Y/Y jump in total revenue. Net profit also rose 23%, as the company again recorded strong revenue growth, despite the impact of Hurricane Sandy on the Northeast regional provider of diagnostic testing for physicians. Revenue per patient rose 4% in the latest quarter, while the number of patients served rose 12%. 1 Comment [Healthcare, Earnings, On the Move]
Thursday, December 6, 2012, 8:38 AM Bio-Reference Laboratories (BRLI): FQ4 EPS of $0.46 in-line. Revenue of $176.1M (+16% Y/Y) in-line. (PR) Comment! [Earnings, Healthcare]
Thursday, August 30, 2012, 2:40 PM Shares of Bio-Reference Laboratories (BRLI -9.5%) get hammered, despite its FQ3 beating on its bottom line earlier today. Net earnings rose 25% Y/Y, as the clinical-testing company's streak of double-digit revenue growth continued, but investors appear to be taking advantage of near 52-week highs to lock in profits as sales growth shows signs of stagnating. 1 Comment [Healthcare, Earnings, On the Move]
Thursday, August 30, 2012, 8:45 AM Bio-Reference Laboratories (BRLI): Q2 EPS of $0.45 beats by $0.03. Revenue of $172.3M (+16.4% Y/Y) in-line. Shares +4.4% premarket. (PR) 1 Comment [Earnings, Healthcare, On the Move]
Thursday, August 30, 2012, 12:05 AM Notable earnings before Thursday’s open: BRLI, CIEN, TD Comment! [Earnings]
Wednesday, August 29, 2012, 5:30 PM Notable earnings before Thursday’s open: BRLI, CIEN, TD 1 Comment [Earnings]
Tuesday, June 12, 2012, 11:47 AM Bio-Reference Labs (BRLI +6.5%) pops after BofA Merrill Lynch ups the shares to Buy, citing how the returns on the commercialization of its high-end tests in a number of high-growth specialty niches are starting to bear fruit. Additionally, reimbursement headwinds and new billing codes are more likely to disproportionately impact small players, which gives BRLI the opportunity to capture market share. Comment! [Healthcare, On the Move]
Thursday, June 7, 2012, 8:42 AM Bio-Reference Laboratories (BRLI): FQ2 EPS of $0.33 beats by $0.01. Revenue of $163.4M (+18.7% Y/Y) beats by $3M. (PR) Comment! [Earnings, Healthcare]
Thursday, March 1, 2012, 11:25 AM Bio-Reference Laboratories (BRLI +9.1%) pops after beating FQ1 estimates earlier. Revenue jumped 23% Y/Y on double digit sales growth as the clinical-testing company's patient count has risen and its share of complex, non-routine testing services continues to grow. Comment! [Healthcare, Earnings, On the Move]
Thursday, March 1, 2012, 8:48 AM Bio-Reference Laboratories (BRLI): FQ1 EPS of $0.26 beats by $0.05. Revenue of $150M (+23% Y/Y) beats by $7M. (PR) Comment! [Earnings, Healthcare]
Thursday, December 8, 2011, 10:13 AM Bio-Reference Laboratories (BRLI +5.4%) gains after reporting Q3 results that beat estimates by a slim margin. The embattled firm says it expects to increase net revenues by more than 15% and net income by around 20% in 2012. Comment! [On the Move]